So, until now, the main treatments that actually work in the acute phase are thrombolysis and thrombectomy. But what we see is that perfusion or reperfusion is different from actually having a clinical improvement. So these strategies that are actually being tested, like for example inflammation, or for groups of neuroprotection, or even use of drugs to try to control edema might have an add-on effect and then actually help to improve these patients in a clinical setting not just talking about reperfusion but actually adding something that actually can lead to actual clinical improvement...
So, until now, the main treatments that actually work in the acute phase are thrombolysis and thrombectomy. But what we see is that perfusion or reperfusion is different from actually having a clinical improvement. So these strategies that are actually being tested, like for example inflammation, or for groups of neuroprotection, or even use of drugs to try to control edema might have an add-on effect and then actually help to improve these patients in a clinical setting not just talking about reperfusion but actually adding something that actually can lead to actual clinical improvement. I think the most promising one may be inflammation, because we know that’s a very important point, that when you have excess inflammation, you can have worse outcomes, and there are several drugs that are currently being tested. So I think that probably the one that is most promising is probably inflammation. Well, I know that there are some neuroprotectants that are being tested in clinical trials. For a long time, we have talked about neuroprotection. The main problem is where or when should we give those neuroprotectants? But I think that probably that will be the next big revolution. It will be these kind of molecules, neuroprotectants, that may help preserve the brain and may help therefore to protect the ischemic effect.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.